Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 27 articles: HTML format

Single Articles

October 2021
1. CACKOWSKI FC, Heath EI
   Prostate cancer dormancy and recurrence.
   Cancer Lett. 2021 Oct 5. pii: S0304-3835(21)00498.
   PubMed     Abstract available
   
   
   
2. KANAGASABAI T, Li G, Shen TH, Gladoun N, et al
   MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.
   Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00502.
   PubMed     Abstract available
   
   
   September 2021
3. TIAN P, Zhong M, Wei GH
   Mechanistic insights into genetic susceptibility to prostate cancer.
   Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00472.
   PubMed     Abstract available
   
   
   
4. RUIZ DE PORRAS V, Font A, Aytes A
   Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
   Cancer Lett. 2021 Sep 10. pii: S0304-3835(21)00430.
   PubMed     Abstract available
   
   
   August 2021
5. WANG Y, Yu J
   Dissecting multiple roles of SUMOylation in prostate cancer.
   Cancer Lett. 2021;521:88-97.
   PubMed     Abstract available
   
   
   
6. LI Q, Ye L, Zhang X, Wang M, et al
   Corrigendum to "FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling" [Cancer Lett. 402 (2017) 166-176].
   Cancer Lett. 2021 Aug 3. pii: S0304-3835(21)00383.
   PubMed    
   
   
   July 2021
7. CAMPBELL KJ, Leung HY
   Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.
   Cancer Lett. 2021 Jul 31. pii: S0304-3835(21)00378.
   PubMed     Abstract available
   
   
   
8. GAO Y, Liu Y, Liu Y, Peng Y, et al
   UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
   Cancer Lett. 2021;520:172-183.
   PubMed     Abstract available
   
   
   
9. LIANG J, Wang L, Poluben L, Nouri M, et al
   Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
   Cancer Lett. 2021 Jul 10. pii: S0304-3835(21)00340.
   PubMed     Abstract available
   
   
   June 2021
10. YAMADA Y, Beltran H
    The treatment landscape of metastatic prostate cancer.
    Cancer Lett. 2021 Jun 18. pii: S0304-3835(21)00295.
    PubMed     Abstract available
    
    
    
11. JAMROZE A, Chatta G, Tang DG
    Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Cancer Lett. 2021;518:1-9.
    PubMed     Abstract available
    
    
    May 2021
12. HOU Z, Huang S, Li Z
    Androgens in prostate cancer: A tale that never ends.
    Cancer Lett. 2021;516:1-12.
    PubMed     Abstract available
    
    
    
13. FREELAND J, Crowell PD, Giafaglione JM, Boutros PC, et al
    Aging of the progenitor cells that initiate prostate cancer.
    Cancer Lett. 2021;515:28-35.
    PubMed     Abstract available
    
    
    
14. HUANG SB, Thapa D, Munoz AR, Hussain SS, et al
    Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.
    Cancer Lett. 2021;505:24-36.
    PubMed     Abstract available
    
    
    February 2021
15. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available
    
    
    
16. KUMAR S, Prajapati KS, Singh AK, Kushwaha PP, et al
    Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer.
    Cancer Lett. 2021 Feb 5. pii: S0304-3835(20)30637.
    PubMed     Abstract available
    
    
    January 2021
17. SONG J, Yu J, Jeong LS, Lee SK, et al
    A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
    Cancer Lett. 2021;497:54-65.
    PubMed     Abstract available
    
    
    
18. CHEN L, Wang YY, Li D, Wang C, et al
    LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.
    Cancer Lett. 2021 Jan 24. pii: S0304-3835(21)00034.
    PubMed     Abstract available
    
    
    November 2020
19. LEECH M, Osman S, Jain S, Marignol L, et al
    Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics.
    Cancer Lett. 2020 Nov 4. pii: S0304-3835(20)30565.
    PubMed     Abstract available
    
    
    September 2020
20. NIKHIL K, Kamra M, Raza A, Shah K, et al
    Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
    Cancer Lett. 2020 Sep 12. pii: S0304-3835(20)30472.
    PubMed     Abstract available
    
    
    August 2020
21. WANG J, Xu W, Wang B, Lin G, et al
    GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers.
    Cancer Lett. 2020;485:45-55.
    PubMed     Abstract available
    
    
    
22. CHEN D, Chou FJ, Chen Y, Tian H, et al
    Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30396.
    PubMed     Abstract available
    
    
    July 2020
23. BATES M, Boland A, McDermott N, Marignol L, et al
    YB-1: The key to personalised prostate cancer management?
    Cancer Lett. 2020 Jul 15. pii: S0304-3835(20)30361.
    PubMed     Abstract available
    
    
    June 2020
24. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    PubMed     Abstract available
    
    
    May 2020
25. WANG S, Gilbreath C, Kollipara RK, Sonavane R, et al
    Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer.
    Cancer Lett. 2020 May 30. pii: S0304-3835(20)30289.
    PubMed     Abstract available
    
    
    
26. MIRANDA-GONCALVES V, Lameirinhas A, Henrique R, Baltazar F, et al
    The metabolic landscape of urological cancers: New therapeutic perspectives.
    Cancer Lett. 2020;477:76-87.
    PubMed     Abstract available
    
    
    April 2020
27. SIDDIQUI S, Libertini SJ, Lucas CA, Lombard AP, et al
    The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.
    Cancer Lett. 2020 Apr 21. pii: S0304-3835(20)30163.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: